Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Sensex trades above 28,000
Wed, 12 Nov 11:30 am

After opening firm, the Indian Indices are trading at record highs during the morning session. Banking and auto stocks are leading the gainers; while metal stocks are trading in the red.

The BSE-Sensex is trading up 195 points. The NSE-Nifty is trading up 47 points. The BSE Mid Cap index is trading up 0.9% and the BSE Small Cap index is trading up 0.7%. The rupee is trading at 61.49 to the US dollar.

Indian pharma stocks are trading mixed with, Piramal Enterprise and Aurobindo pharma being the leading gainers while Cadila healthcare and Dishman pharma being the leading losers in the pack. Aurobindo pharma has announced that the company has emerged as the highest bidder for acquiring Natrol; which manufactures supplements. Reportedly, the process has reached final stage and will be approved by United States bankruptcy court of district of Delaware. Under the auction process, Aurobindo USA emerged as the highest and best bidder with a bid of US$132.5 million to acquire the assets of Natrol with an agreement to take on certain liabilities. Aurobindo USA believes that Natrol is an excellent strategic fit and provides the right platform for creating a fully-integrated OTC platform in the USA and in other international markets. The acquisition will benefit Aurobindo. Post acquisition Aurobindo will have access to its strong portfolio, having presence in variety of attractive supplements market. Thus this will be a new line of segment for the company. Aurobindo pharma was trading up by 3.8% at the time of writing.

Software stocks are trading mixed today. While Tata Consultancy Services (TCS) is leading the gainers; HCL Tech is leading the losers. India's second largest software firm Infosys, is betting big on software products to revive its fortunes. The company's R&D division, Infosys Labs, has been at the centre of the new CEO Vishal Sikka's efforts to transform the company into a next generation services firm. To this end the company has stated that Infosys Labs will develop and implement new disruptive technologies. At the forefront will be automation technologies as well as artificial intelligence. The company has repositioned the division to focus on these technologies and come up with products that will benefit clients. The stock was trading up 0.3% at the time of writing.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Sensex trades above 28,000". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.